HIF-1α Inhibition to Preserve Beta Cell Function in Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diabetes, including insulin, glucose-lowering therapies, and other drugs, fail to effectively maintain or increase insulin levels in patients, leading to the progression of diabetes mellitus, particularly type II, due to the negative impact on beta cell function and insulin resistance.

Innovation Solution

Administration of a HIF-1α inhibitor, such as PX-478, to prevent or delay the onset and progression of diabetes by maintaining or increasing non-fasting plasma insulin and c-peptide levels, thereby supporting pancreatic beta cell function and compensatory mechanisms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If current glucose-lowering therapies (insulin, metformin, sulfonylureas) are administered, then blood glucose levels are reduced, but beta cell function deteriorates and insulin levels decrease over time

Engineering Contradiction:

Improveblood glucose levelVSAvoidbeta cell function

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

Instead of directly lowering blood glucose through conventional mechanisms (insulin secretion stimulation or insulin sensitivity improvement), the patent inverts the approach by targeting HIF-1α inhibition to preserve beta cell function and endogenous insulin production. This indirect approach maintains the beta cell compensatory response rather than bypassing it, thereby resolving the contradiction between glucose control and beta cell preservation

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent introduces HIF-1α inhibition as an intermediary mechanism between glucose metabolism and beta cell function. By inhibiting HIF-1α, the therapy indirectly protects beta cells from hypoxia-induced dysfunction and apoptosis, thereby maintaining both glucose control and beta cell viability without the direct negative effects of conventional therapies

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If insulin secretagogues (sulfonylureas) are administered to increase insulin secretion, then blood glucose control is improved, but long term beta cell function is negatively impacted

Engineering Contradiction:

Improveinsulin secretionVSAvoidbeta cell function duration

Core Design Contradiction:

Quantity of substanceVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary protection to beta cells by inhibiting HIF-1α before hypoxia-induced damage occurs. This preventive approach preserves beta cell function and endogenous insulin production capacity before it deteriorates, avoiding the need for long-term insulin secretagogue use that ultimately fails to maintain beta cell function

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful effect of hypoxia (which normally leads to beta cell dysfunction) into a beneficial therapeutic target. By inhibiting HIF-1α, the pathway that would normally be activated by hypoxia to cause beta cell damage is blocked, thereby transforming a pathological mechanism into a therapeutic opportunity for preserving beta cell function

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Quantity of substance

If beta cell compensation mechanisms are allowed to proceed naturally, then insulin resistance is compensated, but the compensatory response cannot be sustained and diabetes progresses

Engineering Contradiction:

Improveinsulin productionVSAvoidcompensatory response duration

Core Design Contradiction:

Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent provides beforehand cushioning to the beta cell compensatory response by inhibiting HIF-1α. This prevents the hypoxia-induced exhaustion that normally limits the duration of beta cell compensation, thereby extending the sustainable period of insulin production and delaying diabetes progression

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Solution Approach 2:

The patent changes the physiological parameter of HIF-1α activity in beta cells from activated (hypoxic state leading to dysfunction) to inhibited (normoxic-like state preserving function). This parameter change enables sustained beta cell compensation by preventing the metabolic stress that would otherwise lead to compensatory failure

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12491172B2Treatment of diabetes

Publication Date: 2025.12.09 PEREIRA TERESA

AI summary

Disclosed herein is the use of a HIF-1α inhibitor for preventing, delaying or treating diabetes mellitus in a subject. The subject is susceptible to, or has diabetes mellitus and has elevated non-fasting blood glucose, and/or elevated fasting blood glucose, and/or impaired glucose tolerance and/or elevated hemoglobin A1c levels. In particular, the present disclosure relates to the use of a HIF-1α inhibitor, wherein the HIF-1α inhibitor is administered to the subject, thereby maintaining or providing increased non-fasting plasma insulin levels in said subject.